[ CAS No. 189954-96-9 ] {[proInfo.proName]}

Name: 189954-96-9|3-(Cyclopropylmethoxy)-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one|99%
Brand: Ambeed
SKU: A196334
Price: 12.0 USD
Availability: InStock
Rating: 96 (30 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 189954-96-9 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 189954-96-9 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 189954-96-9 ]

SDS Specification

Alternatived Products of [ 189954-96-9 ]

Product Details of [ 189954-96-9 ]

CAS No. :	189954-96-9	MDL No. :	MFCD09837800
Formula :	C₁₇H₂₀O₅S	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	FULAPETWGIGNMT-UHFFFAOYSA-N
M.W :	336.40	Pubchem ID :	208910
Synonyms :	ML 1785713	Chemical Name :	3-(Cyclopropylmethoxy)-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one

Calculated chemistry of [ 189954-96-9 ]

Physicochemical Properties

Num. heavy atoms :	23
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.47
Num. rotatable bonds :	5
Num. H-bond acceptors :	5.0
Num. H-bond donors :	0.0
Molar Refractivity :	86.26
TPSA :	78.05 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	Yes
CYP2C19 inhibitor :	Yes
CYP2C9 inhibitor :	Yes
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-6.83 cm/s

Lipophilicity

Log Po/w (iLOGP) :	2.54
Log Po/w (XLOGP3) :	2.15
Log Po/w (WLOGP) :	3.58
Log Po/w (MLOGP) :	2.02
Log Po/w (SILICOS-IT) :	3.15
Consensus Log Po/w :	2.69

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-3.14
Solubility :	0.242 mg/ml ; 0.000719 mol/l
Class :	Soluble
Log S (Ali) :	-3.42
Solubility :	0.128 mg/ml ; 0.000379 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-4.89
Solubility :	0.00428 mg/ml ; 0.0000127 mol/l
Class :	Moderately soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	0.0
Synthetic accessibility :	3.39

Safety of [ 189954-96-9 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 189954-96-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 189954-96-9 ]

[ 189954-96-9 ] Synthesis Path-Downstream 1~29

1
[ 246869-15-8 ]
[ 189954-96-9 ]

Yield	Reaction Conditions	Operation in experiment
94%	With isopropyl Trifluoroacetate; 1,8-diazabicyclo[5.4.0]undec-7-ene In acetonitrile for 12h; Reflux;	4a Example-4a: Preparation of Firocoxib 2-Methyl-l-[4-(methylsulfonyl)phenyl]-l-oxopropan-2-yl(cyclopropylmethoxy) acetate (100 g; 0.28 mol) and acetonitrile (500 mL) were added into a flask. Isopropyl trifluoroacetate (44 g; 0.28 mol) was then added and stirred. DBU (47 g; 0.31 mol) was added, stirred, heated to reflux temperature and stirred for 12 hours. After completion of the reaction, reaction mass was cooled to 25 to 35 °C, pH of the reaction mass was adjusted to 3 to 5 using dilute HCl. The solid obtained was filtered and washed with water (100 mL) then dried under vacuum to obtain Firocoxib polymorph B. Yield: 89 g; 94%. Purity: 99.1%.
77%	With isopropyl Trifluoroacetate; 1,8-diazabicyclo[5.4.0]undec-7-ene In N,N-dimethyl-formamide at 80 - 100℃; Inert atmosphere;	5 Preparation of 3- (cyclopropylmethoxy) -5,5-dimethyl-4- (4-methanesulfonylphenyl) -2 (5H) -furanone The product of the previous step (0.1061 g) and DBU (0.09 mL) were dissolved in DMF (5 mL) under argon.Stirring evenly, adding isopropyl trifluoroacetate (0.05mL), heating to 80 ~ 100 reaction 10 ~ 13 hours.TLC monitoring, the reaction is complete.Cooled to room temperature, poured into water (15mL), precipitation of white crystals, filtration, natural drying white fluffy crystals, the yield of 77%.
	With 1,8-diazabicyclo[5.4.0]undec-7-ene In acetonitrile

4.78 g

With isopropyl Trifluoroacetate; 1,8-diazabicyclo[5.4.0]undec-7-ene In toluene at 95℃; for 12h;

6; 7 Example 6 Compound (I) (6.26 g, tert-butyl impurity B was enriched in an amount of 11.75%) was dissolved in toluene (31 mL), and DBU (8.06 g) and isopropyl trifluoroacetate (4.41 g) were added and heated. The reaction was stirred at 95 ° C for 12 hours (the reaction solution was sampled and detected, and the tert-butyl impurity C content was 6.75%). The heating was stopped, the reaction liquid was naturally cooled to room temperature, distilled under reduced pressure until no fraction was discharged, and then water (31 mL) was slowly added dropwise, and the solid was gradually precipitated. After the completion of the dropwise addition, the mixture was stirred at room temperature for 2 hours, suction filtered, and filtered cake water (10 mL×2) After washing, a solid wet product was obtained, and the content of the tert-butyl impurity C was 2.63%.The solid wet product was added to absolute ethanol (18 mL), heated to complete dissolution, and then the mixture was stirred and then warmed to room temperature and stirred for 12 hours, filtered, and the solid was washed with ethanol (3 mL×2). The obtained solid was dried at 50 ° C to obtain a rofecoxib, a white solid of 4.78 g, and a tert-butyl impurity C content of 0.06%.

Reference： [1]Current Patent Assignee: SEQUENT SCIENT - WO2018/109781, 2018, A1 Location in patent: Page/Page column 24
[2]Current Patent Assignee: CHINA PHARMACEUTICAL UNIVERSITY - CN105859664, 2016, A Location in patent: Paragraph 0019; 0020
[3]Leblanc; Roy; Boyce; Brideau; Chan; Charleson; Gordon; Grimm; Guay; Leger; Li; Riendeau; Visco; Wang; Webb; Xu; Prasit [Bioorganic and Medicinal Chemistry Letters, 1999, vol. 9, # 15, p. 2207 - 2212]
[4]Current Patent Assignee: SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD - CN109810031, 2019, A Location in patent: Paragraph 0061; 0062; 0063; 0064; 0065; 0066

2
[ CAS Unavailable ]
[ 189954-96-9 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 5 steps 1: AlCl₃ / cyclohexane 2: NaOH, Aliquot 336 / toluene; CCl₄ 3: Oxone 4: CMC, DMAP / CH₂Cl₂ 5: DBU / acetonitrile

3
[ 53207-58-2 ]
3-(Cyclopropylmethoxy)-5.5-dimethyl-4-(4-(methylsulfonyl)phenyl)-5H-furan-2-one [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,1999,vol. 9,p. 2207 - 2212
[2]Patent: CN105859664,2016,A
[3]Patent: WO2018/109781,2018,A1
[4]Patent: WO2018/188763,2018,A1

4
[ 71867-98-6 ]
[ 189954-96-9 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 3 steps 1: Oxone 2: CMC, DMAP / CH₂Cl₂ 3: DBU / acetonitrile
	Multi-step reaction with 4 steps 1: pyridine / dichloromethane / 4 h / 40 °C 2: Aliquat 336; sodium tungstate (VI) dihydrate; dihydrogen peroxide / dichloromethane; water / 3 h / 22 °C 3: 1,8-diazabicyclo[5.4.0]undec-7-ene / acetonitrile / 4 h / 72 °C 4: potassium carbonate / N,N-dimethyl-formamide / 2 h / 80 °C

Reference： [1]Leblanc; Roy; Boyce; Brideau; Chan; Charleson; Gordon; Grimm; Guay; Leger; Li; Riendeau; Visco; Wang; Webb; Xu; Prasit [Bioorganic and Medicinal Chemistry Letters, 1999, vol. 9, # 15, p. 2207 - 2212]
[2]Current Patent Assignee: FINANZIARIA IMMOBILIARE DI PARTECIPAZIONI E COSTRUZIONI SPA ABBREVIABILE IN FIMP - WO2018/188763, 2018, A1

5
[ 246869-08-9 ]
3-(Cyclopropylmethoxy)-5.5-dimethyl-4-(4-(methylsulfonyl)phenyl)-5H-furan-2-one [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 2 steps 1: CMC, DMAP / CH₂Cl₂ 2: DBU / acetonitrile
	Multi-step reaction with 4 steps 1: thionyl chloride; N,N-dimethyl-formamide / dichloromethane / 10 - 35 °C 2: triethylamine / dichloromethane / 0 - 20 °C 3: 1,8-diazabicyclo[5.4.0]undec-7-ene; isopropyl Trifluoroacetate / toluene / 100 °C 4: copper(l) iodide; (2S,4R)-N-(2,6-dimethylphenyl)-4-hydroxypyrrolidine-2-carboxamide; potassium phosphate / dimethyl sulfoxide / 24 h / 90 °C / Inert atmosphere

Reference： [1]Leblanc; Roy; Boyce; Brideau; Chan; Charleson; Gordon; Grimm; Guay; Leger; Li; Riendeau; Visco; Wang; Webb; Xu; Prasit [Bioorganic and Medicinal Chemistry Letters, 1999, vol. 9, # 15, p. 2207 - 2212]
[2]Current Patent Assignee: JIANGSU JUNRUO MEDICINE; NANJING JUNRUO BIO MEDICINE RES INSTITUTE - CN110105314, 2019, A

6
[ 180048-73-1 ]
[ 189954-96-9 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 2 steps 1: CMC, DMAP / CH₂Cl₂ 2: DBU / acetonitrile
	Multi-step reaction with 3 steps 1: triethylamine; dmap / dichloromethane / 0 °C 2: 1,8-diazabicyclo[5.4.0]undec-7-ene / acetonitrile / 12 h / Reflux 3: tetrabutylammomium bromide; sodium hydroxide / toluene; water / 70 °C
	Multi-step reaction with 4 steps 1: triethylamine / ethyl acetate / 0 - 20 °C 2: isopropyl Trifluoroacetate / acetonitrile / 60 - 80 °C 3: hydrogenchloride / water / 60 - 80 °C / pH <= 3 4: triphenylphosphine; diethylazodicarboxylate / dichloromethane / 2 h / -5 - 10 °C

	Multi-step reaction with 3 steps 1: triethylamine / dichloromethane / 3 h / 20 °C 2: 1,8-diazabicyclo[5.4.0]undec-7-ene / acetonitrile / 12 h / Reflux 3: tetrabutylammomium bromide; sodium hydroxide / toluene / 48 h / 80 °C
	Multi-step reaction with 3 steps 1: triethylamine / dichloromethane / 4 h / 20 °C 2: 1,8-diazabicyclo[5.4.0]undec-7-ene / acetonitrile / 12 h / Reflux 3: tetrabutylammomium bromide; sodium hydroxide / toluene / 48 h / 75 - 80 °C

Reference： [1]Leblanc; Roy; Boyce; Brideau; Chan; Charleson; Gordon; Grimm; Guay; Leger; Li; Riendeau; Visco; Wang; Webb; Xu; Prasit [Bioorganic and Medicinal Chemistry Letters, 1999, vol. 9, # 15, p. 2207 - 2212]
[2]Current Patent Assignee: SICHUAN QINGMU PHARMACEUTICAL - CN107686471, 2018, A
[3]Current Patent Assignee: SICHUAN QINGMU PHARMACEUTICAL - CN108586399, 2018, A
[4]Current Patent Assignee: SHANDONG LUKANG SHELILE PHARMACEUTICAL CO., LTD. - CN110452199, 2019, A
[5]Current Patent Assignee: SHANDONG LUKANG SHELILE PHARMACEUTICAL CO., LTD. - CN110452198, 2019, A

7
[ 400-38-4 ]
[ CAS Unavailable ]
[ 246869-15-8 ]
[ CAS Unavailable ]
[ 189954-96-9 ]

Yield	Reaction Conditions	Operation in experiment
	In water; acetonitrile	4 4) 4) Preparation of 3-(cyclopropylmethoxy)-5,5-dimethyl-4-(4'-methylsulphonylphenyl)-5H-furan-2-one (title compound) A solution of isopropyl trifluoroacetate (1.58 g, 10.1 mmol, 1.2 equiv) and 1,8-diazabicyclo-[5.4.0]-undec-7-ene (2.6 g, 13.5 mmol, 1.6 equiv) in anhydrous acetonitrile (20 ml) is stirred for 15 minutes at room temperature. [2-methyl-1-(4'-methylsulphonylphenyl)-1-oxo-prop-2-yl] 2-(cyclopropylmethoxy)acetate (3.00 g, 8.4 mmol) is then added and the reaction mixture is heated to reflux for 18 hours. After returning the temperature to 40° C., the acetonitrile is partially evaporated and then water (20 ml) is added to the reaction medium. After returning to room temperaure and a few hours of crystallisation, the mixture is filtered in order to recover the expected 3-(cyclopropylmethoxy)-5,5-dimethyl-4-(4'-methylsulphonyl)-5H-furan-2-one. The yield of isolated product is 85%. RMN-1H (200 MHz, CD3COCD3) ppm:

Reference： [1]Current Patent Assignee: C.H. Boehringer Sohn AG & Co. KG - US2003/28036, 2003, A1

Yield	Reaction Conditions	Operation in experiment
		210.2 Step 2 Step 2 3-(Cyclopropylmethoxy)-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-5H-furan-2-one A 50 L flask was charged with the ester from Step 2 (1843 g, 5.20 mol), acetonitrile (23 L), isopropyltrifluoroacetate (1300 g, 8.33 mol), and DBU (1067 g, 7.01 mol). The solution was heated to reflux for 18h. The condensor was replaced with a still head, and 10.5 L of solvent was removed over 3 h. The remaining solution was allowed to cool to 30° C., then transferred into 40 L of 0.3 M HCl with vigourous stirring, and seed crystals. The resulting slurry was stirred at room temperature for 18 h, then filtered. The filter cake was washed with 2*5 L water, 2 L of 50% aqueous ethanol, and 3 L of ether. The solid was air-dried for 1 h, then dried under vacuum overnight to give 1859 g of a white solid (still contains residual water). This material was suspended in 8 L ether, stirred for 26 h, filtered and dried under vacuum to give 1371 g of the title compound. A further 130 g of material was obtained by reprocessing the aqueous acetonitrile and ether filtrate for a total of 1501 g. 1 H NMR (CD3 COCD3) δ 0.28 (2H, m), 0.53 (2H, m), 1.17 (1H, m), 1.66 (6H, s), 3.17 (3H, s), 4.16 (2H, d), 8.03 (4H, s).

9
[ CAS Unavailable ]
[ 189954-96-9 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 5 steps 1: aluminum (III) chloride / chloroform / 1.5 h / -10 °C 2: bromine / cyclohexane; ethyl acetate 3: Oxone / chloroform; water; <i>tert</i>-butyl alcohol / 0 - 50 °C 4: N-ethyl-N,N-diisopropylamine / ethanol / -10 - 20 °C 5: 1,8-diazabicyclo[5.4.0]undec-7-ene; isopropyl Trifluoroacetate / N,N-dimethyl-formamide / 80 - 100 °C / Inert atmosphere
	Multi-step reaction with 4 steps 1.1: aluminum (III) chloride / dichloromethane / 4 h / 10 - 20 °C 2.1: bromine / ethyl acetate / 1 h 2.2: 2 h / 25 - 45 °C 3.1: N-ethyl-N,N-diisopropylamine / methanol / 7 h / 0 °C / Reflux 4.1: isopropyl Trifluoroacetate; 1,8-diazabicyclo[5.4.0]undec-7-ene / acetonitrile / 12 h / Reflux
	Multi-step reaction with 7 steps 1.1: aluminum (III) chloride / dichloromethane / 0.5 h / 22 °C 1.2: 3 h / 22 °C 2.1: bromine / dichloromethane / 1 h / 22 - 30 °C 3.1: sodium hydroxide; Aliquat 336 / dichloromethane; water / 18 h / 22 °C 4.1: pyridine / dichloromethane / 4 h / 40 °C 5.1: Aliquat 336; sodium tungstate (VI) dihydrate; dihydrogen peroxide / dichloromethane; water / 3 h / 22 °C 6.1: 1,8-diazabicyclo[5.4.0]undec-7-ene / acetonitrile / 4 h / 72 °C 7.1: potassium carbonate / N,N-dimethyl-formamide / 2 h / 80 °C

Reference： [1]Current Patent Assignee: CHINA PHARMACEUTICAL UNIVERSITY - CN105859664, 2016, A
[2]Current Patent Assignee: SEQUENT SCIENT - WO2018/109781, 2018, A1
[3]Current Patent Assignee: FINANZIARIA IMMOBILIARE DI PARTECIPAZIONI E COSTRUZIONI SPA ABBREVIABILE IN FIMP - WO2018/188763, 2018, A1

10
[ 88324-55-4 ]
[ 189954-96-9 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 3 steps 1: Oxone / chloroform; water; <i>tert</i>-butyl alcohol / 0 - 50 °C 2: N-ethyl-N,N-diisopropylamine / ethanol / -10 - 20 °C 3: 1,8-diazabicyclo[5.4.0]undec-7-ene; isopropyl Trifluoroacetate / N,N-dimethyl-formamide / 80 - 100 °C / Inert atmosphere
	Multi-step reaction with 5 steps 1: sodium hydroxide; Aliquat 336 / dichloromethane; water / 18 h / 22 °C 2: pyridine / dichloromethane / 4 h / 40 °C 3: Aliquat 336; sodium tungstate (VI) dihydrate; dihydrogen peroxide / dichloromethane; water / 3 h / 22 °C 4: 1,8-diazabicyclo[5.4.0]undec-7-ene / acetonitrile / 4 h / 72 °C 5: potassium carbonate / N,N-dimethyl-formamide / 2 h / 80 °C

Reference： [1]Current Patent Assignee: CHINA PHARMACEUTICAL UNIVERSITY - CN105859664, 2016, A
[2]Current Patent Assignee: FINANZIARIA IMMOBILIARE DI PARTECIPAZIONI E COSTRUZIONI SPA ABBREVIABILE IN FIMP - WO2018/188763, 2018, A1

11
[ 7051-34-5 ]
[ 189955-89-3 ]
[ 189954-96-9 ]

Yield	Reaction Conditions	Operation in experiment
54%	With tetrabutylammomium bromide; sodium hydroxide In water; toluene at 70℃;	15 This example provides a method for preparing feloxiflone: Intermediate E 7.0 g was added to 400 ml of toluene.Stir and dissolve,Add 2.4g of a 50% strength aqueous solution of sodium hydroxide,2.6 ml of cyclopropyl methyl bromide and 0.92 g of tetrabutylammonium bromide,Heat to 70°C for 10-18 hours,Filtrate the filtrate Static liquid,Separate the organic phase,It was dried over anhydrous sodium sulfate and concentrated to dryness to give filarexib in a yield of 54%..
107.27 g	With potassium carbonate In N,N-dimethyl-formamide at 80℃; for 2h;	1.g; 1.h Step (q) preparation of 3-(cyclopropylmethoxy)-5,5-dimethyl-4-[4- (methylsulfonyl)phenyl1furan-2(5H)-one (firocoxib) To a mixture of the wet 3-hydroxy-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]furan- 2(5H)-one (IV) obtained in Step (f) (1 18.8 g), dimethylformamide (725 ml) and K2CO3 (60.77 g) at 22±2°C, cyclopropylmethyl bromide (56.97 g) was added. The mixture was heated to 80±2°C for 2 hours, then it was cooled to 50±2°C. Water (620 ml) was added over a period of at least 30 minutes, maintaining 50±2°C. The mixture was held at 50±2°C for 30 minutes and the crystallization of the product occurred. Water (62 ml) was added over a period of at least 10 minutes. The suspension was cooled to 22±2°C and held at that temperature for at least 4 hours. The suspension was filtered and the product was washed with water (370 ml) to give 150.0 g of wet crude Firocoxib as light beige solid. The wet crude Firocoxib was used in the subsequent step without drying. Step h) crystallization of 3-(cyclopropylmethoxy)-5,5-dimethyl-4-[4- (methylsulfonyl)phenyl1furan-2(5H)-one (Firocoxib)A mixture of the wet crude 3-(cyclopropylmethoxy)-5,5-dimethyl-4-[4- (methylsulfonyl)phenyl]furan-2(5H)-one (Firocoxib) obtained in Step (g (150.0 g), methanol (777 ml) and charcoal (2.6 g) was heated to 60±2°C. Charcoal was filtered off on celite filter and the filter was washed with methanol (40 ml). Distillation was performed at ordinary pressure until removing 260 ml of solvent. The mixture was cooled to 50±2°C and crystallization of the product occurred. The suspension was cooled to 0-5 °C, held at that temperature for 1 hour, filtered and the product was washed with methanol (100 ml) to give wet Firocoxib (1 13.22 g) that was dried under vacuum at 60 °C to give 107.27 g of Firocoxib as white crystalline solid.Overall yield 61 .0% (referred to thioanisole).HPLC purity: 99.9%
38 g	With tetrabutylammomium bromide; sodium hydroxide In toluene at 80℃; for 48h;	1-3 After the compound (73 g) having the structure shown by the formula VI above is mixed with 600 ml of toluene, 7 g of tetrabutylammonium bromide, 10 g of sodium hydroxide and 70 g of cyclopropylmethyl bromide are added, and the reaction is performed at 80 ° C. for 48 h;The temperature was lowered to room temperature, 600 ml of water was added, and the mixture was allowed to stand for 0.5 h. The phases were separated, concentrated under reduced pressure and reduced to 55-60 ° C, and concentrated to a vacuum of -0.1 MPa until no liquid flowed out. Methanol was added to the system, the temperature was raised to 60-65 ° C, and the temperature was reduced to room temperature in about 5 hours. The white solid powder was obtained by filtration and dried under vacuum at 55 ° C to obtain a compound (38g) having the structure represented by Formula I. The purity of the product was above 99% .

48 g

With tetrabutylammomium bromide; sodium hydroxide In toluene at 75 - 80℃; for 48h;

1-3 After mixing a compound having the structure shown in Formula with 500 mL of toluene until completely dissolved, add tetrabutylammonium bromide (8 g), sodium hydroxide (12 g) and cyclopropylmethyl bromide (80 g), and heat to 75-80 ° C. Reaction for 48h. After the reaction was completed, the temperature was lowered to room temperature, and 600 mL of water was added. After standing for 0.5 h, the phases were separated, and concentrated under reduced pressure (60 ° C, vacuum degree -0.1 MPa) until no liquid flowed out. Methanol was added to the system, the temperature was raised to 65 ° C, and the temperature was lowered to room temperature in about 5 hours. The white solid powder was obtained by filtration, and vacuum drying was performed at a temperature of 55 ° C and a vacuum degree of -0.1 MPa to obtain about 48 g of firocoxib, Product purity is above 99%.

Reference： [1]Current Patent Assignee: SICHUAN QINGMU PHARMACEUTICAL - CN107686471, 2018, A Location in patent: Paragraph 0116-0119
[2]Current Patent Assignee: FINANZIARIA IMMOBILIARE DI PARTECIPAZIONI E COSTRUZIONI SPA ABBREVIABILE IN FIMP - WO2018/188763, 2018, A1 Location in patent: Page/Page column 6; 7; 10; 12; 14; 15; 19
[3]Current Patent Assignee: SHANDONG LUKANG SHELILE PHARMACEUTICAL CO., LTD. - CN110452199, 2019, A Location in patent: Paragraph 0081; 0089; 0090; 0096; 0098; 0104
[4]Current Patent Assignee: SHANDONG LUKANG SHELILE PHARMACEUTICAL CO., LTD. - CN110452198, 2019, A Location in patent: Paragraph 0086; 0093-0096; 0103; 0105; 0112

12
[ 10342-83-3 ]
[ 189954-96-9 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 6 steps 1: sodium hydroxide / N,N-dimethyl-formamide / 20 °C 2: copper(l) iodide; <i>L</i>-proline / dimethyl sulfoxide / 48 h / 100 °C 3: N-Bromosuccinimide / dimethyl sulfoxide / 14 h / 80 °C 4: triethylamine; dmap / dichloromethane / 0 °C 5: 1,8-diazabicyclo[5.4.0]undec-7-ene / acetonitrile / 12 h / Reflux 6: tetrabutylammomium bromide; sodium hydroxide / toluene; water / 70 °C

Reference： [1]Current Patent Assignee: SICHUAN QINGMU PHARMACEUTICAL - CN107686471, 2018, A

13
[ 49660-93-7 ]
[ 189954-96-9 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 5 steps 1: copper(l) iodide; <i>L</i>-proline / dimethyl sulfoxide / 48 h / 100 °C 2: N-Bromosuccinimide / dimethyl sulfoxide / 14 h / 80 °C 3: triethylamine; dmap / dichloromethane / 0 °C 4: 1,8-diazabicyclo[5.4.0]undec-7-ene / acetonitrile / 12 h / Reflux 5: tetrabutylammomium bromide; sodium hydroxide / toluene; water / 70 °C

Reference： [1]Current Patent Assignee: SICHUAN QINGMU PHARMACEUTICAL - CN107686471, 2018, A

14
[ 53207-59-3 ]
[ 189954-96-9 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 4 steps 1: N-Bromosuccinimide / dimethyl sulfoxide / 14 h / 80 °C 2: triethylamine; dmap / dichloromethane / 0 °C 3: 1,8-diazabicyclo[5.4.0]undec-7-ene / acetonitrile / 12 h / Reflux 4: tetrabutylammomium bromide; sodium hydroxide / toluene; water / 70 °C

Reference： [1]Current Patent Assignee: SICHUAN QINGMU PHARMACEUTICAL - CN107686471, 2018, A

15
[ 256339-21-6 ]
[ 189954-96-9 ]

Yield	Reaction Conditions	Operation in experiment
89%	With 3-chloro-benzenecarboperoxoic acid In dichloromethane at 20℃; Schlenk technique; Inert atmosphere;

Reference： [1]Wang, Ming; Qiao, Zongjun; Zhao, Jiaoyan; Jiang, Xuefeng [Organic Letters, 2018, vol. 20, # 19, p. 6193 - 6197]

16
[ 2246341-76-2 ]
[ 189954-96-9 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 2 steps 1: palladium diacetate; potassium <i>tert</i>-butylate; Sodium thiosulfate pentahydrate; tri tert-butylphosphoniumtetrafluoroborate; tetrabutylammomium bromide / dimethyl sulfoxide / 120 °C / Schlenk technique; Inert atmosphere 2: 3-chloro-benzenecarboperoxoic acid / dichloromethane / 20 °C / Schlenk technique; Inert atmosphere

Reference： [1]Wang, Ming; Qiao, Zongjun; Zhao, Jiaoyan; Jiang, Xuefeng [Organic Letters, 2018, vol. 20, # 19, p. 6193 - 6197]

17
[ 1802633-83-5 ]
[ 189954-96-9 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 3 steps 1: isopropyl Trifluoroacetate / acetonitrile / 60 - 80 °C 2: hydrogenchloride / water / 60 - 80 °C / pH <= 3 3: triphenylphosphine; diethylazodicarboxylate / dichloromethane / 2 h / -5 - 10 °C
	Multi-step reaction with 2 steps 1: 1,8-diazabicyclo[5.4.0]undec-7-ene / acetonitrile / 12 h / Reflux 2: tetrabutylammomium bromide; sodium hydroxide / toluene / 48 h / 75 - 80 °C

Reference： [1]Current Patent Assignee: SICHUAN QINGMU PHARMACEUTICAL - CN108586399, 2018, A
[2]Current Patent Assignee: SHANDONG LUKANG SHELILE PHARMACEUTICAL CO., LTD. - CN110452198, 2019, A

18
[ CAS Unavailable ]
[ 189955-89-3 ]
[ 189954-96-9 ]

Yield	Reaction Conditions	Operation in experiment
94.6%	With triphenylphosphine; diethylazodicarboxylate In dichloromethane at -5 - 10℃; for 2h;	8-12 Example 8 Frocoxib Preparation of (3-(cyclopropylmethoxy)-4-(4-methanesulfonyl-phenyl)-5,5-dimethyl-5H-furan-2-one): Compound C (15.0 g, 1.0 eq) was mixed with 90 mL of dichloromethane, then cyclopropylmethanol (4.03 g,1.05 eq) and triphenylphosphine (20.9 g, 1.5 eq) were stirred and cooled to below 0 °C. DEAD (13.9 g, 1.5 eq) was added dropwise, and then the temperature was controlled at -5 to 10 ° C for 1 to 2 h, and the reaction was completely monitored by HPLC. After adding 60 mL of water, the extract was separated, and the organic phase was dried over anhydrous sodium sulfate. Recrystallization from ethanol to give feloxicam, namely: 3-(cyclopropylmethoxy)-4-(4-methanesulfonyl-phenyl)-5,5-dimethyl-5H-furan- 2-ketone, (16.9 g, white solid, yield: 94.6%, HPLC purity: 99.7%).

Reference： [1]Current Patent Assignee: SICHUAN QINGMU PHARMACEUTICAL - CN108586399, 2018, A Location in patent: Paragraph 0040; 0059-0068

19
[ 2247058-20-2 ]
[ 189954-96-9 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 3 steps 1: Aliquat 336; sodium tungstate (VI) dihydrate; dihydrogen peroxide / dichloromethane; water / 3 h / 22 °C 2: 1,8-diazabicyclo[5.4.0]undec-7-ene / acetonitrile / 4 h / 72 °C 3: potassium carbonate / N,N-dimethyl-formamide / 2 h / 80 °C

Reference： [1]Current Patent Assignee: FINANZIARIA IMMOBILIARE DI PARTECIPAZIONI E COSTRUZIONI SPA ABBREVIABILE IN FIMP - WO2018/188763, 2018, A1

20
[ 2286241-83-4 ]
[ 616-38-6 ]
[ 189954-96-9 ]

Yield	Reaction Conditions	Operation in experiment
50%	With sodium metabisulfite; tetrabutylammomium bromide; palladium dichloride; tert-butyl XPhos In N,N-dimethyl-formamide at 120℃; for 12h; Inert atmosphere;

Reference： [1]Wang, Ming; Zhao, Jiaoyan; Jiang, Xuefeng [ChemSusChem, 2019, vol. 12, # 13, p. 3064 - 3068]

21
4-(4-bromophenyl)-3-(cyclopropylmethoxy)-5,5-dimethylfuran-2(5H)-one [ No CAS ]
[ 2386-57-4 ]
3-(Cyclopropylmethoxy)-5.5-dimethyl-4-(4-(methylsulfonyl)phenyl)-5H-furan-2-one [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
82%	With potassium phosphate; copper(l) iodide; (2S,4R)-N-(2,6-dimethylphenyl)-4-hydroxypyrrolidine-2-carboxamide; In dimethyl sulfoxide; at 90℃; for 24h;Inert atmosphere;	nder a nitrogen atmosphere, a 1 L four-neck reaction flask was charged with CuI (4.80 g, 25.2 mmol(2S,4R)-N-(2,6-dimethylphenyl)-4-hydroxypyrrolidine-2-carboxamide(5.9 g, 25.2 mmol), sodium methanesulfonate (67.0 g, 656.3 mmol), K3PO4 (112.5 g, 530 mmol), 4-(4-bromophenyl)-3-(cyclopropylmethoxy) -5,5-Dimethylfuran-2(5H)-one (Formula II) (170 g, 504 mmol) and DMSO (500 mL). After the addition of the material, the system was replaced with nitrogen three times, and then the system was heated to 90 C and stirred for 24 hours. It was naturally cooled to room temperature and the system was diluted with toluene (500 mL). The reaction mixture was passed through a pad of silica gel, and the solvent was evaporated to dryness. The off-white solid was decolorized with CH 2 Cl 2 (600 mL) and activated carbon (10 g) at 30 C, concentrated under reduced pressure to remove CH 2 Cl 2 solvent, and the residue used ethanol (500 mL)Recrystallization gave a white solid, firocoxib (139.1 g, 82%).

Reference： [1]Patent: CN110105314,2019,A .Location in patent: Paragraph 0029-0032

22
[ 2375339-20-9 ]
[ 189954-96-9 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 3 steps 1: triethylamine / dichloromethane / 0 - 20 °C 2: 1,8-diazabicyclo[5.4.0]undec-7-ene; isopropyl Trifluoroacetate / toluene / 100 °C 3: copper(l) iodide; (2S,4R)-N-(2,6-dimethylphenyl)-4-hydroxypyrrolidine-2-carboxamide; potassium phosphate / dimethyl sulfoxide / 24 h / 90 °C / Inert atmosphere

Reference： [1]Current Patent Assignee: NANJING JUNRUO BIO MEDICINE RES INSTITUTE; JIANGSU JUNRUO MEDICINE - CN110105314, 2019, A

23
[ 1890408-92-0 ]
[ 189954-96-9 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 5 steps 1: boron trifluoride / tetrahydrofuran / 8 h / 55 °C 2: potassium permanganate; water / Isopropyl acetate / 2.5 h / 10 °C 3: triethylamine / dichloromethane / 3 h / 20 °C 4: 1,8-diazabicyclo[5.4.0]undec-7-ene / acetonitrile / 12 h / Reflux 5: tetrabutylammomium bromide; sodium hydroxide / toluene / 48 h / 80 °C

Reference： [1]Current Patent Assignee: SHANDONG LUKANG SHELILE PHARMACEUTICAL CO., LTD. - CN110452199, 2019, A

24
[ 1919876-46-2 ]
[ 189954-96-9 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 4 steps 1: potassium permanganate; water / Isopropyl acetate / 2.5 h / 10 °C 2: triethylamine / dichloromethane / 3 h / 20 °C 3: 1,8-diazabicyclo[5.4.0]undec-7-ene / acetonitrile / 12 h / Reflux 4: tetrabutylammomium bromide; sodium hydroxide / toluene / 48 h / 80 °C

Reference： [1]Current Patent Assignee: SHANDONG LUKANG SHELILE PHARMACEUTICAL CO., LTD. - CN110452199, 2019, A

25
[ 300355-18-4 ]
[ 189954-96-9 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 6 steps 1: tetrahydrofuran; diethyl ether / 10 h / 5 - 20 °C 2: boron trifluoride / tetrahydrofuran / 8 h / 55 °C 3: potassium permanganate; water / Isopropyl acetate / 2.5 h / 10 °C 4: triethylamine / dichloromethane / 3 h / 20 °C 5: 1,8-diazabicyclo[5.4.0]undec-7-ene / acetonitrile / 12 h / Reflux 6: tetrabutylammomium bromide; sodium hydroxide / toluene / 48 h / 80 °C

Reference： [1]Current Patent Assignee: SHANDONG LUKANG SHELILE PHARMACEUTICAL CO., LTD. - CN110452199, 2019, A

26
[ 62936-31-6 ]
3-(Cyclopropylmethoxy)-5.5-dimethyl-4-(4-(methylsulfonyl)phenyl)-5H-furan-2-one [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 5 steps 1.1: oxone\|\|potassium monopersulfate triple salt / water; Isopropyl acetate / 48 h / 20 °C 2.1: toluene-4-sulfonic acid; ethylene glycol / toluene / 6 h / 110 °C 2.2: 10 h / 5 - 20 °C 2.3: 3 h 3.1: triethylamine / dichloromethane / 4 h / 20 °C 4.1: 1,8-diazabicyclo[5.4.0]undec-7-ene / acetonitrile / 12 h / Reflux 5.1: tetrabutylammomium bromide; sodium hydroxide / toluene / 48 h / 75 - 80 °C

Reference： [1]Current Patent Assignee: SHANDONG LUKANG SHELILE PHARMACEUTICAL CO., LTD. - CN110452198, 2019, A

27
[ 102697-45-0 ]
[ 189954-96-9 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 4 steps 1.1: toluene-4-sulfonic acid; ethylene glycol / toluene / 6 h / 110 °C 1.2: 10 h / 5 - 20 °C 1.3: 3 h 2.1: triethylamine / dichloromethane / 4 h / 20 °C 3.1: 1,8-diazabicyclo[5.4.0]undec-7-ene / acetonitrile / 12 h / Reflux 4.1: tetrabutylammomium bromide; sodium hydroxide / toluene / 48 h / 75 - 80 °C

Reference： [1]Current Patent Assignee: SHANDONG LUKANG SHELILE PHARMACEUTICAL CO., LTD. - CN110452198, 2019, A

28
[ 189954-96-9 ]
[ CAS Unavailable ]

Yield	Reaction Conditions	Operation in experiment
67%	With potassium <i>tert</i>-butylate; 1-(bromomethyl)-2,4-difluorobenzene In tetrahydrofuran Cooling with ice; Inert atmosphere;

Reference： [1]Latli, Bachir; Gao, Amy; Kvaternick, Valerie; Tecle, Berhane; Pennino, Scott; Yee, Nathan K.; Song, Jeff [Journal of labelled compounds and radiopharmaceuticals, 2020, vol. 63, # 8, p. 386 - 392]

29
[ 189954-96-9 ]
[ 2418558-28-6 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 2 steps 1.1: potassium <i>tert</i>-butylate; 1-(bromomethyl)-2,4-difluorobenzene / tetrahydrofuran / Cooling with ice; Inert atmosphere 2.1: potassium carbonate / acetonitrile / 20 °C / Inert atmosphere 2.2: 14 h / 20 °C / Inert atmosphere

Same Skeleton Products

Related Products

Historical Records

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 189954-96-9 ] {[proInfo.proName]}

Quality Control of [ 189954-96-9 ]

Related Doc. of [ 189954-96-9 ]

Product Details of [ 189954-96-9 ]

Calculated chemistry of [ 189954-96-9 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 189954-96-9 ]

Application In Synthesis of [ 189954-96-9 ]

[ 189954-96-9 ] Synthesis Path-Downstream 1~29

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry